Evidence map›Paper›PMID 33523420›Full record

ArticleHormones (Athens, Greece)2021

Alpha-melanocyte-stimulating hormone during exercise recovery has prognostic value for coronary artery disease.

Dejana Vidojevic, Stefan Seman, Ratko Lasica, Milorad Tesic, Marija Saric Matutinovic, Snezana Jovicic, Svetlana Ignjatovic, Ross Arena, Svetozar Damjanovic, Dejana Popovic

Abstract read
PubMed Publisher
In one paragraph

Article in Hormones (Athens, Greece), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Dejana VidojevicFaculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, Belgrade, 11000, Serbia.
Stefan SemanFaculty of Sport and Physical Education, Balgoja Parovica 156, Belgrade, 11000, Serbia.
Ratko LasicaDivision of Cardiology, University of Belgrade, Visegradska 26, Belgrade, 11000, Serbia.
Milorad TesicDivision of Cardiology, University of Belgrade, Visegradska 26, Belgrade, 11000, Serbia.
Marija Saric MatutinovicFaculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, Belgrade, 11000, Serbia.
Snezana JovicicFaculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, Belgrade, 11000, Serbia.
Svetlana IgnjatovicFaculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, Belgrade, 11000, Serbia.
Ross ArenaDepartment of Physical Therapy, College of Applied Health Sciences, University of Illinois at Chicago, 1919 W. Taylor St, Chicago, IL, 60612, USA.
Svetozar DamjanovicDivision of Endocrinology, Clinical Center of Serbia, University of Belgrade, Dr Subotica 13, Belgrade, 11000, Serbia.
Dejana PopovicFaculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, Belgrade, 11000, Serbia. dejanapopovic@yahoo.co.uk.ORCID http://orcid.org/0000-0002-6647-5872
University of Belgrade · RSCenter for Health, Exercise and Sport Sciences · RSUniversity of Illinois Chicago · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAlpha-melanocyte-stimulating hormone (alpha-MSH) has proven cardiovascular effects and plays a significant role as an endogenous countermeasure to ischemia-reperfusion injury. The aim of the current study was to examine the response of alpha-MSH during exercise in patients diagnosed with coronary artery disease (CAD) and evaluate its value in the assessment of severity and prognosis.

methodsForty subjects with documented CAD (i.e., lesions on coronary angiography ≥ 50%) were included. Cardiopulmonary exercise testing (CPET) on a treadmill (TM) and recumbent ergometer (RE) were performed on two visits, 2-4 days apart, during 2 months of coronary angiography; subsequently, the subjects were followed up for 32 ± 10 months. At rest, at peak CPET, and after 3 min of recovery, plasma levels of alpha-MSH were measured by enzyme-linked immunosorbent assay technique.

resultsMean ejection fraction was 56.7 ± 9.6%. Alpha-MSH similarly increased from rest to peak CPET on both modalities. There were no significant differences in alpha-MSH values during testing in patients with 1,2- and 3-vesel CAD, nor in patients with a SYNTAX score </≥ 23 (p > 0.05). Among CPET and hormonal parameters, ∆alpha-MSH recovery/peak during RE CPET was the best predictor of cardiac event occurrence (chi-square 6.67, HR = 0.51, CI = 0.25-1.02, p = 0.010).

conclusion∆alpha-MSH recovery/peak during RE CPET has predictive value for CAD prognosis, demonstrating involvement of alpha-MSH in CAD and a link between stress hormones and cardiac events.

Indexed as

alpha-MSHCoronary Artery DiseaseCoronary AngiographyExercise TestHumansPrognosisalpha-MSHAlpha-melanocyte-stimulating hormoneCardiopulmonary exercise testCoronary artery disease

Identifiers

PMID33523420
OpenAlexW3128275296

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.